Vivodyne

Vivodyne’s human data platform enables biopharma teams to validate novel targets, optimize leads, and enhance trial design across any modality

Vivodyne generates human data at AI scale with autonomous labs testing the most realistic human tissues ever grown outside the body

Vivodyne says its HIVE robotic labs generate human-tissue data that AI drug-discovery models lack. The machines grow 20 kinds of tissue and autonomously dose and monitor experiments; Vivodyne says its tissue models show high predictive accuracy in tests involving toxicity, airway behavior, and chemotherapy drugs. The company, which has raised just under $80 million, recently opened a human data center near San Francisco and says it works with multiple major pharmaceutical companies.

Aug 2026TechCrunchNews article

Vivodyne operates a network of 12 robotic **HIVE** labs capable of running **3.1 million human tissue experiments annually**, exceeding the scale of all U.S. clinical trials combined. The company, founded from **University of Pennsylvania** bioengineering research, positions its system as the world’s largest biological datacenter. Vivodyne’s facilities are based in **San Francisco and Philadelphia**.

Aug 2026BioBuzzNews article

Vivodyne introduces the world’s largest human biological datacenter, featuring **12 robotic HIVE laboratories** and a **wafer-scale TissueDisk** to enable **3.1 million annual living human tissue experiments**. The infrastructure supports training for the first global model of human biology. Vivodyne’s system integrates automated labs and scalable tissue-based research to advance biological data processing.

Aug 2026Yahoo FinanceNews article

Vivodyne develops technology to convert human tissues into structured, searchable data formats. The company aims to address gaps in understanding physiology, biology, and disease mechanisms by creating scalable analytical tools. Founded by a bioengineering and robotics expert, Vivodyne targets unexplored areas in medical research through data-driven approaches.

Jan 2026Onyx NewsroomNews article